Effects of combined oral contraceptives on hemostasis in women of late reproductive age
- Авторы: Tarasova M.A.1, Ryabceva I.T.1, Grigorieva V.A.1, Shapovalova K.A.1
-
Учреждения:
- I.P. Pavlov State Medical University
- Выпуск: Том 48, № 5S (1999)
- Страницы: 157-157
- Раздел: Статьи
- Статья получена: 22.02.2022
- Статья одобрена: 22.02.2022
- Статья опубликована: 15.12.1999
- URL: https://journals.eco-vector.com/jowd/article/view/101455
- DOI: https://doi.org/10.17816/JOWD101455
- ID: 101455
Цитировать
Полный текст
Аннотация
Objective: To investigate the effects of combined oral contraceptives (COCs) on hemostasis in women of late reproductive and perimenopausal age.
Полный текст
Objective: to investigate the effects of combined oral contraceptives (COCs) on hemostasis in women of late reproductive and perimenopausal age.
Methods: 64 women within the age interval of 35-49 years were accepted to the study. Three different formulations of COCs were used: 20 g ethinylestradiol with 150 g desogestrel, 30 g ethinylestrad with 150 g desogestrel and 30 g ethinylestradiol with 300 g norgestrel. 13 different parameters of hemostasis including resistance to activated protein C (APC resistance) and presence of Lupus anticoagulant were evaluated at the commencement of the study and after 2 and 6 cycles of COCs intake. The presence of Lupus anticoagulant was detected using tissue thromboplastin inhibition test. Test for identification of the factor V Leiden mutation based on polymerize chain reaction (PCR) was performed as well.
Results: There was a significant reduction of APC-ratio in heterozygous carriers of factor V Leiden as compared to women without this mutation (2,1±0,1 and 2,7±0,1; p<0,01). The presence of lupus anticoagulant was identified more frequently in women with the factor V Leiden mutation using COCs (p,0,01). There was a significant reduction of APC-ratio in these women as well (1,7±0,1 and 2,1±0,1; p<0,01). APC resistance was diagnosed in 3,1% of the participants without the factor V Leiden mutation before the treatment and in 14,1% - after COCs use (p<0,05). The prevalence of APC-resistance was higher in COC users with Lupus anticoagulant as compared to those without this anticoagulant (25,0% - 8,7%, p<0,05).
Conclusions: Apparently APS-resistance and Lupus anticoagulant may be involved in the development of thrombophilia associated with COC use.
Об авторах
M. A. Tarasova
I.P. Pavlov State Medical University
Автор, ответственный за переписку.
Email: info@eco-vector.com
Россия, St. Petersburg
I. T. Ryabceva
I.P. Pavlov State Medical University
Email: info@eco-vector.com
Россия, St. Petersburg
V. A. Grigorieva
I.P. Pavlov State Medical University
Email: info@eco-vector.com
Россия, St. Petersburg
K. A. Shapovalova
I.P. Pavlov State Medical University
Email: info@eco-vector.com
Россия, St. Petersburg